In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Zogenix (ZGNX), with a price target of $65. The company’s shares closed yesterday at $47.48.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.5% and a 39.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Zogenix is a Strong Buy with an average price target of $62.60, which is a 31.8% upside from current levels. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Based on Zogenix’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.2 million. In comparison, last year the company had a GAAP net loss of $29.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
